» Articles » PMID: 19718781

Antisense Oligonucleotide Treatment for a Pseudoexon-generating Mutation in the NPC1 Gene Causing Niemann-Pick Type C Disease

Overview
Journal Hum Mutat
Specialty Genetics
Date 2009 Sep 1
PMID 19718781
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Niemann-Pick type C disease is an autosomal recessive disorder caused by mutations in either the NPC1 or NPC2 gene. While most of the mutations are missense, a few splicing mutations have also been described. We identified and characterized a novel point mutation c.1554-1009G>A located in intron 9 of the NPC1 gene in a Spanish patient. Sequencing of the cDNA from the patient showed that this intronic mutation creates a cryptic donor splice site resulting in the incorporation of 194 bp of intron 9 as a new exon (pseudoexon) in the mRNA. This new transcript bears a premature termination codon and is degraded by the nonsense-mediated mRNA decay mechanism. Experimental confirmation that the point mutation generates the inclusion of a pseudoexon in the mRNA was obtained using a minigene. A specific antisense morpholino oligonucleotide targeted to the cryptic splice site was designed and transfected into fibroblasts from the patient. Using this approach, normal splicing was restored. These results demonstrate the importance of screening deep intronic regions and support the efficacy of antisense therapeutics for the treatment of diseases caused by pseudoexon-generating mutations.

Citing Articles

Expansion of Splice-Switching Therapy with Antisense Oligonucleotides.

Takeshima Y Int J Mol Sci. 2025; 26(5).

PMID: 40076889 PMC: 11899878. DOI: 10.3390/ijms26052270.


Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.

Chen S, Heendeniya S, Le B, Rahimizadeh K, Rabiee N, Zahra Q BioDrugs. 2024; 38(2):177-203.

PMID: 38252341 PMC: 10912209. DOI: 10.1007/s40259-024-00644-7.


Challenges in the Definitive Diagnosis of Niemann-Pick Type C-Leaky Variants and Alternative Transcripts.

Encarnacao M, Ribeiro I, David H, Coutinho M, Quelhas D, Alves S Genes (Basel). 2023; 14(11).

PMID: 38002933 PMC: 10671040. DOI: 10.3390/genes14111990.


Therapeutic Strategies For Tay-Sachs Disease.

Picache J, Zheng W, Chen C Front Pharmacol. 2022; 13:906647.

PMID: 35865957 PMC: 9294361. DOI: 10.3389/fphar.2022.906647.


Analysis of Pathogenic Pseudoexons Reveals Novel Mechanisms Driving Cryptic Splicing.

Keegan N, Wilton S, Fletcher S Front Genet. 2022; 12:806946.

PMID: 35140743 PMC: 8819188. DOI: 10.3389/fgene.2021.806946.